Melinta Therapeutics Signs $90 Million Financing Agreement with Oberland Capital to Fund Baxdela™ Commercial Activities and Expansion into Additional Indications New Haven, Conn, June 29, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, has entered into a loan and...

Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) - Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...